Stanford Translational Cardio-Oncology Program
About the program
The Stanford Translational Cardio-Oncology Program is a rich, collaborative, and multi-disciplinary program which employs clinical data, bio-banked samples, animal and cellular models to study the cardiotoxic mechanisms of oncologic drugs and discover cures. Utilizing close collaborations across disciplines such as oncology and immunology, it aims to build pipelines for biobanking, clinical data gathering, clinical protocol optimization, and basic science discovery efforts to provide treatments for cardio-oncologic diseases and improve clinical care of the cardio-oncology patient population.
The goal of the Stanford Translational Cardio-Oncology Program is to facilitate bench-to-bedside research in the field of cardio-oncology and cardio-immunology in order to bring diagnostic tools and therapeutic solutions to patients.
Monthly Cardio-Oncology Seminar Series
The monthly Stanford Cardio-Oncology seminar series is a multi-disciplinary conference that focuses on one topic a month. The goal is to educate attendees about the newest cutting-edge clinical and research knowledge in the field of cardio-oncology. Conferences feature speakers from both inside and outside Stanford, and provides a vibrant forum to form potential collaborations to form innovative solutions to patient-oriented problems in the field. The seminar also provides attendees and especially trainees opportunities to network with leaders in the field. Past conferences have focused on a variety of topics, including anthracycline-induced cardiotoxicity, tyrosine kinase inhibitor cardiotoxicity, immune checkpoint inhibitor myocarditis, clonal hematopoiesis of indeterminate potential (CHIP), building a multi-disciplinary cardio-oncology program, and challenging and difficult clinical case presentations.
The conference occurs on one Tuesday of every month from 4-5 pm by Zoom. For more details and Zoom link, contact CVI faculty members, Drs. Han Zhu and Paul Cheng.